Annual EBIT
-$195.54 M
-$5.03 M-2.64%
December 31, 2024
Summary
- As of March 10, 2025, FATE annual earnings before interest & taxes is -$195.54 million, with the most recent change of -$5.03 million (-2.64%) on December 31, 2024.
- During the last 3 years, FATE annual EBIT has risen by +$21.45 million (+9.89%).
- FATE annual EBIT is now -1370.22% below its all-time high of -$13.30 million, reached on December 31, 2011.
Performance
FATE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$47.01 M
+$5.37 M+10.24%
December 31, 2024
Summary
- As of March 10, 2025, FATE quarterly earnings before interest & taxes is -$47.01 million, with the most recent change of +$5.37 million (+10.24%) on December 31, 2024.
- Over the past year, FATE quarterly EBIT has increased by +$5.37 million (+10.24%).
- FATE quarterly EBIT is now -1263.43% below its all-time high of -$3.45 million, reached on March 31, 2013.
Performance
FATE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$195.54 M
+$1.06 M+0.54%
December 31, 2024
Summary
- As of March 10, 2025, FATE TTM earnings before interest & taxes is -$195.54 million, with the most recent change of +$1.06 million (+0.54%) on December 31, 2024.
- Over the past year, FATE TTM EBIT has increased by +$1.06 million (+0.54%).
- FATE TTM EBIT is now -5257.23% below its all-time high of -$3.65 million, reached on September 30, 2012.
Performance
FATE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
FATE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.6% | +10.2% | +0.5% |
| 3 y3 years | +9.9% | +10.2% | +0.5% |
| 5 y5 years | -102.8% | +10.2% | +0.5% |
FATE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.6% | +36.6% | -64.4% | +45.6% | -2.6% | +37.6% |
| 5 y | 5-year | -102.8% | +36.6% | -69.3% | +45.6% | -102.8% | +37.6% |
| alltime | all time | -1370.2% | +36.6% | -1263.4% | +45.6% | -5257.2% | +37.6% |
Fate Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$195.54 M(+2.6%) | -$47.01 M(-10.2%) | -$195.54 M(-0.5%) |
| Sep 2024 | - | -$52.38 M(+16.2%) | -$196.60 M(+0.6%) |
| Jun 2024 | - | -$45.08 M(-11.7%) | -$195.50 M(-8.2%) |
| Mar 2024 | - | -$51.07 M(+6.2%) | -$212.99 M(+11.8%) |
| Dec 2023 | -$190.51 M(-38.2%) | -$48.08 M(-6.2%) | -$190.51 M(-7.9%) |
| Sep 2023 | - | -$51.28 M(-18.0%) | -$206.85 M(-14.5%) |
| Jun 2023 | - | -$62.56 M(+118.8%) | -$241.97 M(-7.8%) |
| Mar 2023 | - | -$28.59 M(-55.6%) | -$262.51 M(-14.9%) |
| Dec 2022 | -$308.39 M(+42.1%) | -$64.42 M(-25.4%) | -$308.39 M(-1.6%) |
| Sep 2022 | - | -$86.39 M(+3.9%) | -$313.35 M(+11.3%) |
| Jun 2022 | - | -$83.11 M(+11.6%) | -$281.58 M(+14.8%) |
| Mar 2022 | - | -$74.47 M(+7.3%) | -$245.25 M(+13.0%) |
| Dec 2021 | -$216.99 M(+69.4%) | -$69.38 M(+27.0%) | -$216.99 M(+19.9%) |
| Sep 2021 | - | -$54.62 M(+16.8%) | -$181.01 M(+14.7%) |
| Jun 2021 | - | -$46.78 M(+1.2%) | -$157.88 M(+12.9%) |
| Mar 2021 | - | -$46.21 M(+38.4%) | -$139.80 M(+9.1%) |
| Dec 2020 | -$128.09 M(+32.9%) | -$33.40 M(+6.1%) | -$128.09 M(+4.6%) |
| Sep 2020 | - | -$31.49 M(+9.7%) | -$122.45 M(+4.5%) |
| Jun 2020 | - | -$28.71 M(-16.8%) | -$117.17 M(+5.1%) |
| Mar 2020 | - | -$34.49 M(+24.2%) | -$111.53 M(+15.7%) |
| Dec 2019 | -$96.40 M(+48.5%) | -$27.76 M(+5.9%) | -$96.40 M(+14.4%) |
| Sep 2019 | - | -$26.21 M(+13.6%) | -$84.23 M(+13.3%) |
| Jun 2019 | - | -$23.07 M(+19.2%) | -$74.37 M(+5.4%) |
| Mar 2019 | - | -$19.36 M(+24.1%) | -$70.53 M(+8.7%) |
| Dec 2018 | -$64.90 M | -$15.60 M(-4.6%) | -$64.90 M(+5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$16.35 M(-15.0%) | -$61.39 M(+10.9%) |
| Jun 2018 | - | -$19.23 M(+40.1%) | -$55.34 M(+21.5%) |
| Mar 2018 | - | -$13.72 M(+13.6%) | -$45.55 M(+9.3%) |
| Dec 2017 | -$41.68 M(+31.0%) | -$12.09 M(+17.3%) | -$41.68 M(+12.0%) |
| Sep 2017 | - | -$10.31 M(+9.3%) | -$37.21 M(+5.5%) |
| Jun 2017 | - | -$9.43 M(-4.3%) | -$35.26 M(+4.3%) |
| Mar 2017 | - | -$9.86 M(+29.5%) | -$33.80 M(+6.2%) |
| Dec 2016 | -$31.82 M(+14.6%) | -$7.61 M(-8.9%) | -$31.82 M(+2.3%) |
| Sep 2016 | - | -$8.35 M(+4.8%) | -$31.12 M(+7.0%) |
| Jun 2016 | - | -$7.97 M(+1.1%) | -$29.09 M(+2.7%) |
| Mar 2016 | - | -$7.89 M(+14.2%) | -$28.34 M(+2.0%) |
| Dec 2015 | -$27.77 M(+9.6%) | -$6.91 M(+9.3%) | -$27.77 M(+3.6%) |
| Sep 2015 | - | -$6.32 M(-12.4%) | -$26.80 M(-0.3%) |
| Jun 2015 | - | -$7.22 M(-1.5%) | -$26.90 M(+4.6%) |
| Mar 2015 | - | -$7.32 M(+23.2%) | -$25.72 M(+1.5%) |
| Dec 2014 | -$25.33 M(+26.1%) | -$5.94 M(-7.4%) | -$25.33 M(+2.3%) |
| Sep 2014 | - | -$6.42 M(+6.2%) | -$24.75 M(+2.4%) |
| Jun 2014 | - | -$6.04 M(-12.9%) | -$24.18 M(+2.5%) |
| Mar 2014 | - | -$6.94 M(+29.4%) | -$23.59 M(+17.4%) |
| Dec 2013 | -$20.10 M(+46.1%) | -$5.36 M(-8.2%) | -$20.10 M(+5.9%) |
| Sep 2013 | - | -$5.84 M(+7.3%) | -$18.98 M(+13.1%) |
| Jun 2013 | - | -$5.45 M(+57.9%) | -$16.78 M(+48.0%) |
| Mar 2013 | - | -$3.45 M(-18.7%) | -$11.34 M(+43.7%) |
| Dec 2012 | -$13.75 M(+3.4%) | -$4.24 M(+16.1%) | -$7.89 M(+116.1%) |
| Sep 2012 | - | -$3.65 M | -$3.65 M |
| Dec 2011 | -$13.30 M | - | - |
FAQ
- What is Fate Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Fate Therapeutics?
- What is Fate Therapeutics annual EBIT year-on-year change?
- What is Fate Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Fate Therapeutics?
- What is Fate Therapeutics quarterly EBIT year-on-year change?
- What is Fate Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Fate Therapeutics?
- What is Fate Therapeutics TTM EBIT year-on-year change?
What is Fate Therapeutics annual earnings before interest & taxes?
The current annual EBIT of FATE is -$195.54 M
What is the all time high annual EBIT for Fate Therapeutics?
Fate Therapeutics all-time high annual earnings before interest & taxes is -$13.30 M
What is Fate Therapeutics annual EBIT year-on-year change?
Over the past year, FATE annual earnings before interest & taxes has changed by -$5.03 M (-2.64%)
What is Fate Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of FATE is -$47.01 M
What is the all time high quarterly EBIT for Fate Therapeutics?
Fate Therapeutics all-time high quarterly earnings before interest & taxes is -$3.45 M
What is Fate Therapeutics quarterly EBIT year-on-year change?
Over the past year, FATE quarterly earnings before interest & taxes has changed by +$5.37 M (+10.24%)
What is Fate Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of FATE is -$195.54 M
What is the all time high TTM EBIT for Fate Therapeutics?
Fate Therapeutics all-time high TTM earnings before interest & taxes is -$3.65 M
What is Fate Therapeutics TTM EBIT year-on-year change?
Over the past year, FATE TTM earnings before interest & taxes has changed by +$1.06 M (+0.54%)